WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526964
CAS#: 319425-66-6
Description: CF-1743 is a highly potent anti-varicella zoster virus nucleoside. CF-1743 proved to be significantly more potent than all reference anti-VZV compounds as measured either by inhibition of infectious virus particles and/or by viral DNA load.
Hodoodo Cat#: H526964
Name: CF-1743
CAS#: 319425-66-6
Chemical Formula: C22H26N2O5
Exact Mass: 398.18
Molecular Weight: 398.459
Elemental Analysis: C, 66.32; H, 6.58; N, 7.03; O, 20.08
Synonym: CF-1743; CF 1743; CF1743.
IUPAC/Chemical Name: 3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
InChi Key: MFGSDSRTGUVZQG-DFQSSKMNSA-N
InChi Code: InChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
SMILES Code: O=C1N=C(OC(C2=CC=C(CCCCC)C=C2)=C3)C3=CN1[C@@H]4O[C@H](CO)[C@@H](O)C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: 1: De Clercq E. Selective anti-herpesvirus agents. Antivir Chem Chemother. 2013 Jan 23;23(3):93-101. doi: 10.3851/IMP2533. Review. PubMed PMID: 23343513. 2: Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, Henson GW, Morris A. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011 Jun;55(6):2847-54. doi: 10.1128/AAC.01446-10. PubMed PMID: 21444712; PubMed Central PMCID: PMC3101458. 3: Derudas M, Quintiliani M, Brancale A, Andrei G, Snoeck R, Balzarini J, McGuigan C. Evaluation of novel phosphoramidate ProTides of the 2'-fluoro derivatives of a potent anti-varicella zoster virus bicyclic nucleoside analogue. Antivir Chem Chemother. 2010 Oct 28;21(1):15-31. doi: 10.3851/IMP1661. PubMed PMID: 21045257. 4: McGuigan C, Derudas M, Quintiliani M, Andrei G, Snoeck R, Henson G, Balzarini J. 2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6264-7. doi: 10.1016/j.bmcl.2009.09.116. PubMed PMID: 19833513. 5: McGuigan C, Balzarini J. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. J Antimicrob Chemother. 2009 Oct;64(4):671-3. doi: 10.1093/jac/dkp294. Review. PubMed PMID: 19679595. 6: De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. doi: 10.1517/14728214.13.3.393 . Review. PubMed PMID: 18764719. 7: McGuigan C, Pathirana RN, Migliore M, Adak R, Luoni G, Jones AT, Díez-Torrubia A, Camarasa MJ, Velázquez S, Henson G, Verbeken E, Sienaert R, Naesens L, Snoeck R, Andrei G, Balzarini J. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother. 2007 Dec;60(6):1316-30. PubMed PMID: 17956908. 8: Jarvis CA, McGuigan C, Heard CM. In vitro delivery of novel, highly potent anti-varicella zoster virus nucleoside analogues to their target site in the skin. Pharm Res. 2004 Jun;21(6):914-9. PubMed PMID: 15212153. 9: De Clercq E. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Med Res Rev. 2003 May;23(3):253-74. Review. PubMed PMID: 12647310. 10: Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol. 2002 May;61(5):1140-5. PubMed PMID: 11961132.
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 398.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |